Although the programme was very comprehensive, the Symposium was designed to provide time for both formal and informal exchange of information. The technical presentations were organized into concurrent sessions with grouped papers on related topics. Abstracts for each paper (except two that were not available when going to press) and each poster are included here and the proceedings of the Symposium will be published as a CD-Rom early in 1999. Full presentations of several of these papers will appear in later editions of this journal.
Integrating drug discovery technologies ames A. Bristol, Parke-Davis Pharmaceutical Research, Ann Arbor, MI, USA The pharmaceutical industry today is entering a new era wherein a number of new and enabling technologies are maturing simultaneously. These enabling technologies include combinatorial chemistry, ultra-high-throughput screening, genomics, pharamacogenomics, proteomics, data management, high-throughput methodology for toxicology, and ADME parameters. In addition, new and improved automation techniques will have a dramatic impact on optimization of these new technologies. At the same time, the unprecedented productivity and financial success of new pharmaceutical agents and the effect of mergers leading to vastly larger single companies have created unprecedented demands for continued improvements in productivity that will be translated directly to increased sales and profits. A further factor is the increasing trend to outsource key discovery and development activities to biopharmaceutical companies and contract research organizations. These enabling technologies have the potential to transform pharmaceutical discovery into a highly efficient technological advanced process which will demand appropriate resourcing and integration for optimal efficiency. These developments are the challenges for drug discovery scientists in the future who, in addition to having established expertise within their own scientific disciplines, will necessarily have to work effectively at the interface of these intersecting technologies and scientific disciplines.
Coordinated development of multi-site/multifunctional analytical robotics applications: challenges and visions E. F. McNiff, Bristol-Myers Squibb, Princeton, NJ, USA The analytical development laboratory provides multiple opportunities for increasing productivity through automation and robotics. Today's generation of analytical scientists has arrived on the job accustomed to using and developing automated approaches to their work. They expect automation, and where it does not exist, will seek to add it. There are many approaches to automation of an analytical technique. The approach can vary depending on the scope and impact of the application, but also whether it is being developed by an analytical scientist or an engineer. A challenge exists in maintaining the automation creativity of individual scientists, while providing a mechanism for an integrated and coordinated approach to development within a multi-site, multifunctional organization. From a diverse mix of analytical chemists, biochemists, process control scientists, software developers and mechanical engineers, have come a wide range of automated systems. An overview of these systems will be provided with emphasis on the successes and challenges of the various development approaches which were utilized. The ongoing evolution into the current team approach to automation development will be presented.
Quality control: organization, cycle times, compliance and efficiency j. M. Hawkins, Janssen Pharmaceutica, Titusville, NJ, USA Understanding the contributions that the laboratory can make in product/process development, process improvement, market surveillance and general business is key to the pharmaceutical business today. Poor laboratory practice yields compliance issues, increased cost, increased cycle time and delayed product introductions. In my presentation, I hope to prompt discussion and gain agreement and recognition of the laboratory's contribution in meeting the expectations of our pharmaceutical customers. I will cover key areas of customer satisfaction, genomics, combinatorial chemistry and molecular modelling, provides pharmaceutical companies with therapeutic opportunities never before possible. HTS involves using automated equipment to test a large number of samples against a novel molecular or cellular target to identify a reasonable number of active molecules in a timely fashion. Under the best of circumstances, the active molecules identified by HTS can be the chemical leads which will be optimized into important new marketed drugs. Because most drug discovery efforts fail to result in a marketed drug, the primary pressure on HTS is to do more--more targets and more test samples--to increase the likelihood of success.
Many HTS groups within pharmaceutical companies have done more through the use of automation, improved process design and hard work. It is now common for HTS groups to test several hundred thousand samples against 20 or more novel targets each year. These levels of productivity are roughly 10- Concepts in automation, data management and streamlined assay design which have been developed within the HTS environment will be applied to other aspects of drug discovery, e.g. target validation and secondary screening. Broader adoption of the tools of HTS may be able to achieve improvements in drug discovery time lines and cost savings which cannot occur through more and faster HTS.
Libraries of molecules, screening and optimization of hits: a cost-effective approach Nigel R. A. Beeley, Amylin Pharmaceuticals, San Diego, CA,
USA
As a product-oriented biotechnology company we need inexpensive solutions for acquiring libraries of molecules, introducing screening robotics, handling data and automating chemistry when compared to the larger pharmaceutical companies and technology-oriented start-up companies. We now have access to over 250000 compounds for screening purposes from the following: (i) pharmacophore-based selective purchasing from several purveyors of compounds; (ii) risk-sharing arrangements giving access to relatively large numbers of compounds; and (iii) participation in a combinatorial chemistry consortium. We have put in place the necessary informatics and screening robotics to identify hits and analyse data from the above. In addition, we have re-tooled our chemistry effort to tbcus on optimization of hits, making extensive use of parallel synthesis. Some recent examples from our anti-obesity and anti-diabetic programs will be presented.
The HTS infrastructure---the right tools for the task Mark Beggs, Janssen Research Foundation, Belgium High-throughput screening (HTS) is a key component of the pharmaceutical lead identification process atJanssen Research Foundation. Over recent years, the pharmaceutical industry has experienced significant increases in the throughput capabilities of its HTS functions. In those companies where HTS has been effectively deployed, it is now possible to screen the entire corporate compound collection against a pharmacological target within a timescale of several weeks to a few months. This capability has been realized, not as a result of the purchase of any one particular piece of hardware, but rather through the development of a truly effective HTS infrastructure which matches the needs of the parent organization. Central to this development is the need to understand how to effectively combine the use of the different types of hardware available to the HTS specialist. 
Germany
In the past 10 years, laboratory automation (previously used primarily in clinical-chemical analysis) became a more important tool for routine testing in pharmaceutical quality control. The use of automated or semi-automated laboratory equipment can decrease the lab flow-through time of the samples for release testing of raw materials and finished products as well as for stability studies, thus saving manual capacity for other analytical work. Therefore, to improve elticiency, the first automated equipment was introduced into the quality control labs of Byk Gulden in the early 1990s. These instruments were prototype robotic systems which automated the release testing of an X-ray contrast medium and stability studies of enteric coated tablets (including assay and purity testing). After the implementation and qualification phase (approx. year for each system), the equipment has been used over a period of about 4 years for routine testing and benchmarking studies. The results show that the lab flow through time for the samples of one contrast medium batch can be cut in half using the automated method compared to the corresponding manual procedure (8 h instead of 16 h). The number of batches that can be tested per day, week or month is no longer limited by the working hours of the analysts, but only by the capacity of the equipment. Due to these positive experiences, a further automated instrument was ordered in January 1998 for the analysis of a new X-ray contrast medium produced for the USA market. The first economical data for this robotic system show the same significant drop in the lab flow-through time of the samples as m.a. tbr the other robotic systems (10 h instead of 20 h). observed in the range of 0.100-10ng/ml (r > 0.9997).
Observed recoveries for methylphenidate at 0.300 ng/ml, 3.999ng/ml and 7.998ng/ml were 72.0%, 66.8% and 68.7%, respectively. The between-batch CV% for QC samples at 0.100ng/ml, 0.300ng/1, 3.999ng/ml and 7.998 ng/ml were 7.6%, 5.0%, 4.0% and 3.5%, respectively. Further validation and stability data will be presented. Besides the automatic capability, the system also offers the possibility of diameter's correction, either automatic, semi-automatic or manual, so that the user can observe the effects of content value. An automatic transfer of data to a worksheet is also available. In order to maintain pace with HTS, a sample supply strategy is required which will respond rapidly to screening requests, provide the flexibility screeners want, and maintain control and accountability for the quality of samples produced. To achieve these goals, Glaxo Wellcome has developed an automated sample storage, retrieval and processing system with the capacity of 3 million samples and an output rate of 15 million samples per year. The automated liquid store (ALS) comprises an environmentally conditioned sample storage facility and an input/output buffer integrated with three liquid handling robots (LHRs). The system will perform sample replication and discrete sample picking from 384-well source blocks into either 96-or 384-well microtitre plates.
The scale of this facility has called for an industrial design concept which is modular to allow reconfiguration of the LHRs to meet future business needs whilst maintaining the core storage and retrieval infrastructure. This presentation will review the role of the ALS in the GW sample supply strategy, its principle elements and functions, and the approach taken to managing the project.
A robotic compound dissolution system for the The quality of data generated in screens may be compromised by the instability of compounds delivered to those screens. 'Just in time' dilution of compounds will help to maintain the stability of these compounds. The ability to delivery gl of compound in neat DMSO to a variety of target plates is the basis for just in time compound delivery and paramount to increasing the quality of screening data generated in those targets. This also eliminates a dilution step in the compound handling system, thus decreasing the time spent preparing compound plates for the numerous targets being screened. The technical detail of the architecture for laboratory automation systems built using the component-based framework will be described in this presentation. The interactions between the system coordinator, the system repository, system scheduler, system logger and other peripheral components will be presented in the context of the underlying services-based architecture. Description of the communication interfaces between various components of an automated system will be explained. Several design patterns were used to develop this architecture. The influence of these patterns on the design of laboratory automation systems will be addressed. Also, the influence of unified modelling language on interface design will be discussed. Integration of the system components with the peripheral components to build an automated system based on this framework will be presented with emphasis on run-time configuration and component reuse. In addition, the integration of this architecture with enterprise applications, e.g. MS Exchange and MS IIS will be addressed. The development of a laboratory component based on this framework will also be described. 
